Bill · H.R. 4573· House(119-HR-4573)
Innovate to Save Lives Act
- Introduced
- 7/21/2025
- Last activity
- 7/21/2025 — Referred to the House Committee on Ways and Means.
- Sponsored by
- Joe Neguse
- Cosponsors
- - 2 - 3
- Introduced
- In Committee
What this bill would do
The Innovate to Save Lives Act proposes an amendment to the Internal Revenue Code of 1986. It seeks to provide a tax credit to small businesses for research activities aimed at mitigating certain drug threats. This credit would amount to 10 percent of qualified drug threat mitigation research expenses. The bill defines specified drugs to include fentanyl, fentanyl-related substances, methamphetamine, and emerging drugs. The legislation also requires a report from the Comptroller General five years after enactment.
Yes· 3 of 11
Does this do more about addiction and overdose deaths?+6
The bill funds research into mitigating the effects of drugs like fentanyl and methamphetamine, which are central to the opioid crisis.
Does this cut taxes for small businesses?+5
The bill provides a 10 percent tax credit for small businesses performing research related to drug threat mitigation.
Does this make it easier to run a small business?+5
The act directly supports small businesses by offering financial relief through tax credits for specific research activities.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Financial Support for Small Businesses: Small businesses engaging in research to discover information related to mitigating or treating the effects of certain drug use, or to prevent, divert, or intervene in such use, would receive a credit of 10 percent of their qualified research expenses (Section 2(a)).
-
Targeted Research on Dangerous Substances: The bill focuses on high-risk substances such as fentanyl, fentanyl-related substances, methamphetamine, and emerging drug threats (Section 2(b)(3)).
Potential Negative Impacts for People
- Restrictions on Clinical Research: Research intended to address drug threats may not qualify for the credit if it is clinical research that does not comply with the specific policies and guidelines of the National Institutes of Health (Section 2(b)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Economy And Finance
- Improves Small Business Support+5Reduces Small Business Taxes+5Improves Economic Growth+2
- Healthcare
- Improves Opioid Crisis Response+6Increases Research Funding+5
- Demographic And Interest Groups
- Good For Business Owners+5Good For Low Income Households+2Good For Urban Residents+2
- Education And Technology
- Increases Scientific Research Funding+5
- Governance And Ideology
- Improves Government Transparency+2
- Social Issues And Justice
- Improves Poverty Reduction+2
- 7/21/2025
- Referred to the House Committee on Ways and Means.
- 5 Cosponsors added.
- Introduced in House
Don BaconRepublican · Nebraska
Juan CiscomaniRepublican · Arizona
Madeleine DeanDemocrat · Pennsylvania
Maxine DexterDemocrat · Oregon
Michael LawlerRepublican · New York